| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 3.275 +3.05% on 02/05/24 | | 5.200 -35.10% on 01/08/24 | -1.725 (-33.82%) since 01/05/24 |
| 3-Month | 3.275 +3.05% on 02/05/24 | | 5.800 -41.81% on 01/05/24 | -1.975 (-36.92%) since 11/03/23 |
| 52-Week | 3.275 +3.05% on 02/05/24 | | 11.500 -70.65% on 03/06/23 | -7.750 (-69.66%) since 02/03/23 |
LONDON, UK / ACCESSWIRE / October 11, 2021 / ReNeuron has announced that the nine-patient Phase IIa (2m cell dose) extension study (halted in June after a presumed eye infection case) has fully restarted...
LONDON, UK / ACCESSWIRE / January 15, 2021 / After an eventful 2020, ReNeuron released updated 12-month Phase ll data in January on its lead human retinal progenitor cell (hRPC) project. This continues...
LONDON, UK / ACCESSWIRE / August 26, 2020 / ReNeuron has refocussed onto its human retinal progenitor cell (hRPC) as shown in the last business update and in the FY20 results. hRPC, now the lead project,...
| 3rd Resistance Point | 3.717 |
| 2nd Resistance Point | 3.608 |
| 1st Resistance Point | 3.492 |
| Last Price | 3.375 |
| 1st Support Level | 3.267 |
| 2nd Support Level | 3.158 |
| 3rd Support Level | 3.042 |
| 52-Week High | 11.500 |
| Fibonacci 61.8% | 8.358 |
| Fibonacci 50% | 7.387 |
| Fibonacci 38.2% | 6.417 |
| Last Price | 3.375 |
| 52-Week Low | 3.275 |